New hope for rare leukemia: drug duo enters human testing
NCT ID NCT07283640
First seen Jan 03, 2026 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This early-phase trial tests whether combining two drugs, blinatumomab and revumenib, is safe for adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a KMT2A gene change. The study includes people whose cancer has returned or not responded to treatment, as well as older or frail newly diagnosed patients. The main goal is to find the best dose and watch for side effects in 20 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLINATUMOMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.